Edgewise Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US28036F1057 (EWTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
1
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. Read full profile
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€148.87M - EBIT margin
0.0% - Net income
-€128.54M - Net margin
0.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
|
|
|
|
| Carruthers R Michael | Chief Financial Officer |
|
|
|
|
| Derakhshan Behrad | Chief Business Officer |
|
|
|
|
| Donovan Joanne M. | CMO |
|
|
|
|
| KOCH KEVIN | President and CEO |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Andreas Halvorsen |
|
|
|
Sell |